| [ XLS ] |
| ||||||||||
|
|
Merck Serono |
Consumer |
Pharmaceuticals |
Group/ Continuing Operations | ||||||
|
€ million |
2007 |
2006 |
2007 |
2006 |
2007 |
2006 |
2007 |
2006 | ||
|
Sales |
4,187.0 |
1,902.4 |
418.2 |
398.3 |
4,605.2 |
2,300.7 |
6,775.1 |
4,440.1 | ||
|
Royalty income |
270.7 |
12.0 |
1.5 |
1.5 |
272.2 |
13.5 |
282.0 |
19.5 | ||
|
Total revenues |
4,457.7 |
1,914.4 |
419.7 |
399.8 |
4,877.4 |
2,314.2 |
7,057.1 |
4,459.6 | ||
|
Gross margin |
3,764.7 |
1,420.6 |
283.7 |
263.9 |
4,048.4 |
1,684.5 |
5,277.3 |
2,892.3 | ||
|
Selling, general and administration |
–1,980.9 |
–781.8 |
–210.0 |
–197.2 |
–2,190.9 |
–979.0 |
–2,717.1 |
–1,466.1 | ||
|
Research and development |
–878.6 |
–471.5 |
–12.0 |
–10.4 |
–890.6 |
–481.9 |
–1,027.7 |
–615.4 | ||
|
Operating result |
356.9 |
162.9 |
59.6 |
54.5 |
416.5 |
217.4 |
976.0 |
798.6 | ||
|
Exceptional items |
–743.6 |
–21.9 |
– |
– |
–743.6 |
–21.9 |
–775.6 |
232.6 | ||
|
Earnings before interest and tax (EBIT) |
–386.7 |
141.0 |
59.6 |
54.5 |
–327.1 |
195.5 |
200.4 |
1,031.2 | ||
|
Net operating assets |
9,884.8 |
2,841.5 |
281.0 |
276.0 |
10,165.8 |
3,117.5 |
12,179.9 |
5,122.1 | ||
|
Segment liabilities |
–799.0 |
–272.3 |
–54.5 |
–55.0 |
–853.5 |
–327.3 |
–1,128.0 |
–607.4 | ||
|
Capital spending on property, plant and equipment |
147.6 |
69.9 |
6.1 |
4.5 |
153.7 |
74.4 |
263.3 |
219.5 | ||
|
Investments in intangible assets |
91.7 |
38.5 |
0.8 |
1.0 |
92.5 |
39.5 |
101.6 |
43.1 | ||
|
Net cash flows from operating activities |
875.9 |
147.5 |
50.9 |
59.3 |
926.8 |
206.8 |
1,181.4 |
612.8 | ||
|
Net cash flows from investing activities |
–7,381.0 |
–1,672.4 |
–4.0 |
–0.6 |
–7,385.0 |
–1,673.0 |
–7,525.4 |
–1,385.2 | ||
|
Free cash flow |
–6,505.1 |
–1,524.9 |
46.9 |
58.7 |
–6,458.2 |
–1,466.2 |
–6,307.9 |
–1,195.8 | ||
|
Impairment losses |
–100.2 |
–12.9 |
– |
–0.3 |
–100.2 |
–13.2 |
–109.3 |
–47.5 | ||
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
| ||
|
|
Liquid Crystals |
Performance & |
Chemicals |
Group/ Continuing Operations | ||||||
|
€ million |
2007 |
2006 |
2007 |
2006 |
2007 |
2006 |
2007 |
2006 | ||
|
Sales |
909.4 |
892.4 |
1,231.3 |
1,213.3 |
2,140.7 |
2,105.7 |
6,775.1 |
4,440.1 | ||
|
Royalty income |
6.3 |
2.6 |
3.5 |
3.4 |
9.8 |
6.0 |
282.0 |
19.5 | ||
|
Total revenues |
915.7 |
895.0 |
1,234.8 |
1,216.7 |
2,150.5 |
2,111.7 |
7,057.1 |
4,459.6 | ||
|
Gross margin |
611.3 |
592.0 |
615.1 |
612.9 |
1,226.4 |
1,204.9 |
5,277.3 |
2,892.3 | ||
|
Selling, general and administration |
–42.5 |
–35.8 |
–409.9 |
–388.9 |
–452.4 |
–424.7 |
–2,717.1 |
–1,466.1 | ||
|
Research and development |
–78.8 |
–66.7 |
–58.3 |
–66.7 |
–137.1 |
–133.4 |
–1,027.7 |
–615.4 | ||
|
Operating result |
486.6 |
486.1 |
144.4 |
155.4 |
631.0 |
641.5 |
976.0 |
798.6 | ||
|
Exceptional items |
– |
– |
– |
–34.5 |
– |
–34.5 |
–775.6 |
232.6 | ||
|
Earnings before interest and tax (EBIT) |
486.6 |
486.1 |
144.4 |
120.9 |
631.0 |
607.0 |
200.4 |
1,031.2 | ||
|
Net operating assets |
915.1 |
897.2 |
1,053.0 |
1,073.4 |
1,968.1 |
1,970.6 |
12,179.9 |
5,122.1 | ||
|
Segment liabilities |
–90.0 |
–96.2 |
–176.9 |
–178.0 |
–266.9 |
–274.2 |
–1,128.0 |
–607.4 | ||
|
Capital spending on property, plant and equipment |
48.6 |
72.8 |
57.9 |
68.8 |
106.5 |
141.6 |
263.3 |
219.5 | ||
|
Investments in intangible assets |
1.5 |
0.6 |
7.5 |
2.9 |
9.0 |
3.5 |
101.6 |
43.1 | ||
|
Net cash flows from operating activities |
474.0 |
421.1 |
181.1 |
221.4 |
655.1 |
642.5 |
1,181.4 |
612.8 | ||
|
Net cash flows from investing activities |
–49.2 |
–49.2 |
–49.3 |
–88.9 |
–98.5 |
–138.1 |
–7,525.4 |
–1,385.2 | ||
|
Free cash flow |
424.8 |
371.9 |
131.8 |
132.5 |
556.6 |
504.4 |
–6,307.9 |
–1,195.8 | ||
|
Impairment losses |
–0.2 |
–0.3 |
–8.9 |
–33.7 |
–9.1 |
–34.0 |
–109.3 |
–47.5 | ||
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
| ||
|
|
Corporate |
Discontinued Operations (Generics) |
Reversal Discontinued Operations (Generics) |
Group/ Continuing Operations | ||||||
|
€ million |
2007 |
2006 |
2007 |
2006 |
2007 |
2006 |
2007 |
2006 | ||
|
Sales |
29.2 |
33.7 |
1,391.8 |
1,818.5 |
–1,391.8 |
–1,818.5 |
6,775.1 |
4,440.1 | ||
|
Royalty income |
– |
– |
2.7 |
5.5 |
–2.7 |
–5.5 |
282.0 |
19.5 | ||
|
Total revenues |
29.2 |
33.7 |
1,394.5 |
1,824.0 |
–1,394.5 |
–1,824.0 |
7,057.1 |
4,459.6 | ||
|
Gross margin |
2.5 |
2.9 |
656.8 |
899.1 |
–656.8 |
–899.1 |
5,277.3 |
2,892.3 | ||
|
Selling, general and administration |
–73.8 |
–62.4 |
–364.6 |
–449.5 |
364.6 |
449.5 |
–2,717.1 |
–1,466.1 | ||
|
Research and development |
– |
–0.1 |
–95.3 |
–132.1 |
95.3 |
132.1 |
–1,027.7 |
–615.4 | ||
|
Operating result |
–71.5 |
–60.3 |
188.7 |
306.8 |
–188.7 |
–306.8 |
976.0 |
798.6 | ||
|
Exceptional items |
–32.0 |
289.0 |
3,561.5 |
–13.2 |
–3,561.5 |
13.2 |
–775.6 |
232.6 | ||
|
Earnings before interest and tax (EBIT) |
–103.5 |
228.7 |
3,750.2 |
293.6 |
–3,750.2 |
–293.6 |
200.4 |
1,031.2 | ||
|
Net operating assets |
46.0 |
34.0 |
19.4 |
1,042.3 |
–19.4 |
–1,042.3 |
12,179.9 |
5,122.1 | ||
|
Segment liabilities |
–7.6 |
–5.9 |
–7.5 |
–332.1 |
7.5 |
332.1 |
–1,128.0 |
–607.4 | ||
|
Capital spending on property, plant and equipment |
3.1 |
3.5 |
19.5 |
33.7 |
–19.5 |
–33.7 |
263.3 |
219.5 | ||
|
Investments in intangible assets |
0.1 |
0.1 |
19.5 |
13.5 |
–19.5 |
–13.5 |
101.6 |
43.1 | ||
|
Net cash flows from operating activities |
–400.5 |
–236.5 |
36.9 |
198.9 |
–36.9 |
–198.9 |
1,181.4 |
612.8 | ||
|
Net cash flows from investing activities |
–41.9 |
425.9 |
4,797.9 |
–76.5 |
–4,797.9 |
76.5 |
–7,525.4 |
–1,385.2 | ||
|
Free cash flow |
–406.3 |
–234.0 |
4,834.8 |
122.4 |
–4,834.8 |
–122.4 |
–6,307.9 |
–1,195.8 | ||
|
Impairment losses |
– |
–0.3 |
– |
– |
– |
– |
–109.3 |
–47.5 | ||
